These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 18548093

  • 1. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
    Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvolo V, Corn P, Hanaoka N, Konopleva M, Andreeff M, Nakakuma H.
    Leukemia; 2008 Sep; 22(9):1728-36. PubMed ID: 18548093
    [Abstract] [Full Text] [Related]

  • 2. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.
    Cancer Res; 2009 Apr 15; 69(8):3520-8. PubMed ID: 19351820
    [Abstract] [Full Text] [Related]

  • 3. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
    Guo Y, Li Y, Wang FF, Xiang B, Huang XO, Ma HB, Gong YP.
    Int J Biochem Cell Biol; 2019 Jan 15; 106():8-20. PubMed ID: 30389549
    [Abstract] [Full Text] [Related]

  • 4. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M.
    Blood; 2008 Oct 01; 112(7):2886-95. PubMed ID: 18633130
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
    Kojima K, Konopleva M, Samudio IJ, Ruvolo V, Andreeff M.
    Cancer Res; 2007 Apr 01; 67(7):3210-9. PubMed ID: 17409429
    [Abstract] [Full Text] [Related]

  • 7. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis.
    Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, Jin L, Tabe Y, Nakakuma H.
    Leukemia; 2010 Jan 01; 24(1):33-43. PubMed ID: 19946262
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
    Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M.
    Cell Cycle; 2006 Dec 01; 5(23):2778-86. PubMed ID: 17172851
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.
    Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H.
    Cancer Sci; 2009 Jun 01; 100(6):1128-36. PubMed ID: 19385969
    [Abstract] [Full Text] [Related]

  • 12. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.
    Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M.
    Blood; 2011 Oct 20; 118(16):4431-9. PubMed ID: 21868571
    [Abstract] [Full Text] [Related]

  • 13. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
    Carter BZ, Mak DH, Schober WD, Koller E, Pinilla C, Vassilev LT, Reed JC, Andreeff M.
    Blood; 2010 Jan 14; 115(2):306-14. PubMed ID: 19897582
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells.
    Secchiero P, Zerbinati C, di Iasio MG, Melloni E, Tiribelli M, Grill V, Zauli G.
    Curr Drug Metab; 2007 May 14; 8(4):395-403. PubMed ID: 17504227
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. 1,25-dihydroxyvitamin D3 enhances the apoptotic activity of MDM2 antagonist nutlin-3a in acute myeloid leukemia cells expressing wild-type p53.
    Thompson T, Andreeff M, Studzinski GP, Vassilev LT.
    Mol Cancer Ther; 2010 May 14; 9(5):1158-68. PubMed ID: 20406950
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T, Wang J, Chen X, Meng X, Song X, Lu Z, Jiang H, Liu L.
    Tumour Biol; 2010 Aug 14; 31(4):287-95. PubMed ID: 20422343
    [Abstract] [Full Text] [Related]

  • 20. Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma.
    Drakos E, Atsaves V, Li J, Leventaki V, Andreeff M, Medeiros LJ, Rassidakis GZ.
    Leukemia; 2009 Apr 14; 23(4):784-90. PubMed ID: 19225536
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.